secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2025-08-11T23:59:59+00:00
Accession:  0001708599-25-000091
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina Therapeutics Q2 net loss $6.4M; cash runway into Q4 2025; SER-252 on track for clinic this year
--------------------------------------------------------------------------------

- Net loss $6.4M ($0.66/share) vs prior-year net income $5.2M ($0.61/share).
- Revenue $130k (NIH grants) vs $51k YoY; R&D spend up 100% to $3.2M.
- Cash $6.0M; projects funding into Q4 2025; raised $1.2M net via ATM at avg $5.95.
- Lead candidate SER-252 (POZ-apomorphine) on track for Phase 1 in Q4 2025.
- Advanced SER-270 (once-weekly injectable) for tardive dyskinesia; appointed Dr. Brannan to board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000091/0001708599-25-000091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000170859925000091/ser-20250811.htm
  HTML page:      https://secwatch.observer/filing/0001708599-25-000091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer